BR9812886A - Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável - Google Patents

Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável

Info

Publication number
BR9812886A
BR9812886A BR9812886-8A BR9812886A BR9812886A BR 9812886 A BR9812886 A BR 9812886A BR 9812886 A BR9812886 A BR 9812886A BR 9812886 A BR9812886 A BR 9812886A
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
acceptable derivative
receptor
constipated
females
Prior art date
Application number
BR9812886-8A
Other languages
English (en)
Inventor
Allen Wayne Mangel
Allison Ruth Northcutt
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9812886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9812886A publication Critical patent/BR9812886A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"USO DE UM ANTAGONISTA DE RECEPTOR DE 5-HT~ 3~ OU DE UM SEU DERIVADO FARMACEUTICAMENTE ACEITáVEL, PROCESSO PARA TRATAMENTO DE IBS EM FêMEAS NãO-CONSTIPADAS, E, ANTAGONISTA DE RECEPTOR DE 5-HT~ 3~ OU SEU DERIVADO FARMACEUTICAMENTE ACEITáVEL". Esta invenção refere-se ao uso de antagonistas de receptor de 5-HT~ 3~ no tratamento de IBS em pacientes fêmeas não-constipadas.
BR9812886-8A 1997-10-07 1998-10-05 Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável BR9812886A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments
PCT/EP1998/006278 WO1999017755A2 (en) 1997-10-07 1998-10-05 Medicaments

Publications (1)

Publication Number Publication Date
BR9812886A true BR9812886A (pt) 2000-08-08

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812886-8A BR9812886A (pt) 1997-10-07 1998-10-05 Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável

Country Status (36)

Country Link
US (3) US6284770B1 (pt)
EP (1) EP1021174A2 (pt)
JP (1) JP2001518495A (pt)
KR (1) KR20010015707A (pt)
CN (1) CN1281357A (pt)
AP (1) AP2000001785A0 (pt)
AR (1) AR017296A1 (pt)
AU (1) AU750818B2 (pt)
BR (1) BR9812886A (pt)
CA (1) CA2305751A1 (pt)
CO (1) CO5011096A1 (pt)
DZ (1) DZ2618A1 (pt)
EA (1) EA003184B1 (pt)
EE (1) EE200000214A (pt)
GB (1) GB9721139D0 (pt)
GT (1) GT199800157A (pt)
HN (1) HN1998000155A (pt)
HR (1) HRP20000198A2 (pt)
HU (1) HUP0003750A3 (pt)
ID (1) ID23874A (pt)
IL (1) IL135398A0 (pt)
IS (1) IS5425A (pt)
MA (1) MA26549A1 (pt)
NO (1) NO20001776L (pt)
NZ (1) NZ503698A (pt)
PA (1) PA8461101A1 (pt)
PE (1) PE120299A1 (pt)
PL (1) PL340337A1 (pt)
SK (1) SK4862000A3 (pt)
SV (1) SV1998000122A (pt)
TN (1) TNSN98179A1 (pt)
TR (1) TR200000913T2 (pt)
UY (1) UY25200A1 (pt)
WO (1) WO1999017755A2 (pt)
YU (1) YU20600A (pt)
ZA (1) ZA989061B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
JP2003533482A (ja) * 2000-05-18 2003-11-11 グラクソ グループ リミテッド 機能性消化不良の治療方法
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
JP2004508056A (ja) * 2000-09-06 2004-03-18 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
ES2357808T3 (es) * 2001-06-07 2011-04-29 Christine Dr. Sang Tratamiento del dolor neuropático con antagonistas del receptor de n-metil-d-aspartato (nmda).
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
CA2473392A1 (en) 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
WO2004004734A1 (en) * 2002-07-10 2004-01-15 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
PL378369A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
CA2550886A1 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
MXPA05009025A (es) * 2004-01-30 2006-04-27 Astellas Pharma Inc Agentes de tratamiento para el sindrome de intestino delgado irritado con diarrea predominante.
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
AU2005213305A1 (en) * 2004-02-03 2005-08-25 Daniel Rachmilewitz Methods of treating irritable bowel syndrome
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1724267B1 (en) 2004-02-26 2013-11-06 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1902053B1 (en) * 2005-06-07 2011-01-12 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
WO2007097197A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. アミド誘導体またはその塩
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
US8343552B2 (en) 2007-12-28 2013-01-01 Liveleaf, Inc. Therapeutic composition produced using punica granatum and hydrogen peroxide
US8568743B2 (en) 2009-04-29 2013-10-29 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
JP5741433B2 (ja) * 2009-06-30 2015-07-01 アステラス製薬株式会社 緩解期の炎症性腸疾患患者における排便異常治療剤
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
JP2014530249A (ja) * 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
JP2015531346A (ja) 2012-09-05 2015-11-02 チェイス・ファーマスーティカルズ・コーポレーション 抗コリン作用性神経保護組成物及び方法
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254584B1 (en) 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
GB8806990D0 (en) * 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
GB2209335B (en) * 1987-09-03 1991-05-29 Glaxo Group Ltd Lactam derivatives
DE3850742T2 (de) * 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
EP0336759A1 (en) * 1988-04-07 1989-10-11 Glaxo Group Limited Imidazole derivatives
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
AU1161292A (en) * 1991-01-09 1992-08-17 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
EA003184B1 (ru) 2003-02-27
HUP0003750A2 (hu) 2001-10-28
TR200000913T2 (tr) 2001-01-22
NO20001776L (no) 2000-06-06
HUP0003750A3 (en) 2003-02-28
GT199800157A (es) 2000-03-30
WO1999017755A2 (en) 1999-04-15
NZ503698A (en) 2002-10-25
IS5425A (is) 2000-03-31
US20010044450A1 (en) 2001-11-22
YU20600A (sh) 2003-10-31
DZ2618A1 (fr) 2003-03-01
EP1021174A2 (en) 2000-07-26
AU750818B2 (en) 2002-07-25
JP2001518495A (ja) 2001-10-16
HRP20000198A2 (en) 2001-04-30
SV1998000122A (es) 1999-07-05
SK4862000A3 (en) 2001-01-18
AU9629398A (en) 1999-04-27
US6593336B2 (en) 2003-07-15
PA8461101A1 (es) 2000-05-24
PE120299A1 (es) 1999-12-15
GB9721139D0 (en) 1997-12-03
ZA989061B (en) 2001-07-05
NO20001776D0 (no) 2000-04-06
MA26549A1 (fr) 2004-12-20
TNSN98179A1 (fr) 2005-03-15
AP2000001785A0 (en) 2000-06-30
HN1998000155A (es) 1999-05-24
UY25200A1 (es) 2001-01-31
CO5011096A1 (es) 2001-02-28
WO1999017755A3 (en) 1999-09-23
US20030036549A1 (en) 2003-02-20
ID23874A (id) 2000-05-25
IL135398A0 (en) 2001-05-20
US6284770B1 (en) 2001-09-04
AR017296A1 (es) 2001-09-05
US6429209B2 (en) 2002-08-06
CA2305751A1 (en) 1999-04-15
KR20010015707A (ko) 2001-02-26
PL340337A1 (en) 2001-01-29
EE200000214A (et) 2001-06-15
CN1281357A (zh) 2001-01-24
EA200000299A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
BR9812886A (pt) Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável
PT1135153E (pt) Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares
BR9916307A (pt) Derivados quinolina
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
EP1027011A4 (en) ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0116505A (pt) Compostos ou um sal deste farmaceuticamente aceitável, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios onde um antagonista de um receptor de orexina humano é requerido, e, processo para a fabricação de composições farmacêuticas para o tratamento de distúrbios associados com o papel da orexina, especialmente da obesidade e distúrbios do sono
DE69638074D1 (de) Imidazolderivate als histamin-h3-modulatoren
BR9507788A (pt) Composto ou solvato ou sal do mesmo processo para a preparação do composto composição farmacêutica antagonista do receptor de NK3 uso do composto uso do antagonista do receptor de NG3 e processo para o tratamento e/ou profilaxia de distúrbios pulmonares e distúrbios convulsivos
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
BR0016138A (pt) Formulação farmacêutica adequada para a administração intranasal, processo para a preparação de uma formulação farmacêutica estéril, método de tratamento de uma condição de doença na qual o agonismo de receptores 5hti é benéfico, uso de zolmitriptan, dispositivo de administração intranasal, solução aquosa de zolmitriptan, e ,sal de citrato
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
BR9809071A (pt) Agentes farmacológicos
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
BR9813208A (pt) Antagonista receptor de vitronectina
BR0015540A (pt) Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos
BR9801132A (pt) N-heterociclos fundidos, substituìdos com benzilóxi, processo para a sua preparação e seu uso como antagonistas de receptor de bradiquinina.
BR0103913A (pt) Tratamento de combinação para depressão e ansiedade
WO2000048581A3 (en) Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.